NCT02286947View on ClinicalTrials.gov

Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

April 21, 2017

Study Completion Date

March 23, 2018

Conditions
Muscular Dystrophy, Duchenne
Interventions
DRUG

Eteplirsen

Eteplirsen solution for IV infusion

Trial Locations (9)

14642

University of Rochester Medical Center, Rochester

21205

Kennedy Krieger Institute, Baltimore

43205

Nationwide Children's Hospital, Columbus

52242

University of Iowa Children's Hospital, Iowa City

63110

St. Louis Children's Hospital, St Louis

90095

Ronald Reagan UCLA Medical Center, Los Angeles

95817

University of California, Davis Medical Center, Sacramento

98105

Seattle Children's Hospital, Seattle

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Sarepta Therapeutics, Inc.

INDUSTRY

NCT02286947 - Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter